These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 31164373)

  • 1. Clinical Efficacy and Safety of Nivolumab: Results of a
    Okada M; Kijima T; Aoe K; Kato T; Fujimoto N; Nakagawa K; Takeda Y; Hida T; Kanai K; Imamura F; Oizumi S; Takahashi T; Takenoyama M; Tanaka H; Hirano J; Namba Y; Ohe Y
    Clin Cancer Res; 2019 Sep; 25(18):5485-5492. PubMed ID: 31164373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Efficacy and Safety of Nivolumab in Malignant Non-Pleural Mesothelioma: A Multicenter, Open-Label, Single-Arm, Japanese Phase II Trial (Viola) Protocol.
    Kuribayashi K; Igeta M; Daimon T; Ibu M; Suna S; Okamoto R; Kijima T
    Oncology; 2023; 101(4):257-261. PubMed ID: 36566745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma.
    Miyamoto Y; Kozuki T; Aoe K; Wada S; Harada D; Yoshida M; Sakurai J; Hotta K; Fujimoto N
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34711664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study.
    Fujimoto N; Okada M; Kijima T; Aoe K; Kato T; Nakagawa K; Takeda Y; Hida T; Kanai K; Hirano J; Ohe Y
    JTO Clin Res Rep; 2021 Mar; 2(3):100135. PubMed ID: 34589998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
    Disselhorst MJ; Quispel-Janssen J; Lalezari F; Monkhorst K; de Vries JF; van der Noort V; Harms E; Burgers S; Baas P
    Lancet Respir Med; 2019 Mar; 7(3):260-270. PubMed ID: 30660511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial evaluation of nivolumab in patients with post-operative recurrence of malignant pleural mesothelioma.
    Nakamura A; Kondo N; Nakamichi T; Kuroda A; Hashimoto M; Matsumoto S; Yokoi T; Kuribayashi K; Kijima T; Hasegawa S
    Jpn J Clin Oncol; 2020 Aug; 50(8):920-925. PubMed ID: 32463095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
    Calabrò L; Morra A; Fonsatti E; Cutaia O; Fazio C; Annesi D; Lenoci M; Amato G; Danielli R; Altomonte M; Giannarelli D; Di Giacomo AM; Maio M
    Lancet Respir Med; 2015 Apr; 3(4):301-9. PubMed ID: 25819643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma.
    Quispel-Janssen J; van der Noort V; de Vries JF; Zimmerman M; Lalezari F; Thunnissen E; Monkhorst K; Schouten R; Schunselaar L; Disselhorst M; Klomp H; Hartemink K; Burgers S; Buikhuisen W; Baas P
    J Thorac Oncol; 2018 Oct; 13(10):1569-1576. PubMed ID: 29908324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of nivolumab with ipilimumab for recurrent malignant pleural mesothelioma after primary surgical intervention.
    Nakamura A; Hashimoto M; Kondo N; Matsumoto S; Kuroda A; Minami T; Kitajima K; Kuribayashi K; Kijima T; Hasegawa S
    Int J Clin Oncol; 2023 Mar; 28(3):409-415. PubMed ID: 36609928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab for the treatment of unresectable pleural mesothelioma.
    Hotta K; Fujimoto N; Kozuki T; Aoe K; Kiura K
    Expert Opin Biol Ther; 2020 Feb; 20(2):109-114. PubMed ID: 31825692
    [No Abstract]   [Full Text] [Related]  

  • 11. Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).
    Metaxas Y; Früh M; Eboulet EI; Grosso F; Pless M; Zucali PA; Ceresoli GL; Mark M; Schneider M; Maconi A; Perrino M; Biaggi-Rudolf C; Froesch P; Schmid S; Waibel C; Appenzeller C; Rauch D; von Moos R;
    Ann Oncol; 2020 Apr; 31(4):495-500. PubMed ID: 32085891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study.
    Namikawa K; Kiyohara Y; Takenouchi T; Uhara H; Uchi H; Yoshikawa S; Takatsuka S; Koga H; Wada N; Minami H; Hatsumichi M; Asada S; Namba Y; Yamazaki N
    Eur J Cancer; 2018 Dec; 105():114-126. PubMed ID: 30447539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.
    Haakensen VD; Nowak AK; Ellingsen EB; Farooqi SJ; Bjaanæs MM; Horndalsveen H; Mcculloch T; Grundberg O; Cedres SM; Helland Å
    J Transl Med; 2021 May; 19(1):232. PubMed ID: 34059094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma.
    Canova S; Ceresoli GL; Grosso F; Zucali PA; Gelsomino F; Pasello G; Mencoboni M; Rulli E; Galli F; De Simone I; Carlucci L; De Angelis A; Belletti M; Bonomi M; D'Aveni A; Perrino M; Bono F; Cortinovis DL;
    ESMO Open; 2022 Dec; 7(6):100644. PubMed ID: 36463732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world safety of nivolumab in patients with malignant pleural mesothelioma in Japan: post-marketing surveillance study.
    Fujimoto N; Akamatsu A; Honda C; Aoki M; Ohe Y
    Jpn J Clin Oncol; 2024 Sep; ():. PubMed ID: 39225432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
    Calabrò L; Morra A; Fonsatti E; Cutaia O; Amato G; Giannarelli D; Di Giacomo AM; Danielli R; Altomonte M; Mutti L; Maio M
    Lancet Oncol; 2013 Oct; 14(11):1104-1111. PubMed ID: 24035405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.
    Calabrò L; Morra A; Giannarelli D; Amato G; D'Incecco A; Covre A; Lewis A; Rebelatto MC; Danielli R; Altomonte M; Di Giacomo AM; Maio M
    Lancet Respir Med; 2018 Jun; 6(6):451-460. PubMed ID: 29773326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study.
    Cortinovis D; Grosso F; Carlucci L; Zucali PA; Pasello G; Tiseo M; Sperandi F; Hollander L; Galli F; Torri V; Rulli E; Canova S; Maconi A; Bidoli P; Ceresoli GL; D'Incalci M;
    Clin Lung Cancer; 2021 Jul; 22(4):361-370.e3. PubMed ID: 32732073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
    Alley EW; Lopez J; Santoro A; Morosky A; Saraf S; Piperdi B; van Brummelen E
    Lancet Oncol; 2017 May; 18(5):623-630. PubMed ID: 28291584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab Immunotherapy in Malignant Mesothelioma: A Case Report Highlighting a New Opportunity for Exceptional Outcomes.
    Jones RG; Karthik F; Dugar A; Kanagarajan K; Desai K; Bhandari M
    Am J Case Rep; 2018 Jul; 19():783-789. PubMed ID: 29970876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.